A Personalized, Texting-Based Conversational Agent to Address Sleep Disturbance in Individuals Who Have Survived Breast Cancer: Protocol for a Pilot Waitlist Randomized Controlled Trial

TL;DR

This study tests a text-based AI tool called Cecebot to help breast cancer survivors improve their sleep through personalized messaging and support.

Contribution

The study introduces a novel conversational agent that combines CBTi with physical activity support via SMS for breast cancer survivors.

Findings

The Cecebot intervention will be tested for safety, acceptability, and efficacy in improving sleep among breast cancer survivors.

Feasibility will be measured through recruitment, enrollment, and retention rates during the trial.

The study will explore the impact of SMS-based CBTi and physical activity support on sleep outcomes.

Abstract

Sleep disturbance is one of the most common health concerns reported by individuals who have survived breast cancer (BC) and is associated with poor quality of life (QoL) and greater mortality after treatment. Cognitive behavioral therapy for insomnia (CBTi) has shown efficacy for improving sleep and QoL for this population. Considered the gold standard for insomnia treatment, CBTi can be delivered remotely, including via digital intervention. Despite the potential for wider dissemination of CBTi via digital means, these modalities have unique challenges, including technology barriers and poor adherence. We developed a conversational agent (CA) to deliver CBTi via a SMS text messaging intervention, supported by mobile-ready web content. Named “Cecebot,” this CA delivers sleep education, implements sleep compression, provides just-in-time interventions for sleep-disrupting behaviors, and includes enhanced support for physical activity (PA) beyond what is typically included in CBTi. This represents a novel modality for a CBTi and PA intervention among individuals who have survived BC.

We aim to examine the safety and acceptability of the Cecebot intervention, developed by an academic partnership between Dr Reding’s research team and Moby Inc, for individuals who have survived BC and experience symptoms of insomnia, and to explore its efficacy.

This trial will recruit 60 individuals who have survived BC and are experiencing moderate to severe sleep disturbance. Participants will be assigned to the Cecebot intervention or waitlist control group at a 1:1 ratio. The treatment group will receive the Cecebot intervention during weeks 1-6 of the study, while the waitlist control condition will receive the Cecebot intervention during weeks 6-12. The Cecebot intervention uses SMS text messaging technology paired with a Fitbit. Participants will be assessed at baseline, week 6, and week 12. Measurements will include feasibility and acceptability and will explore the effect of the Cecebot intervention. Feasibility will be assessed through recruitment, enrollment, and retention rates. Acceptability will be evaluated using a satisfaction survey and open-ended responses. Quantitative analysis, such as t test, Fisher exact tests, and generalized linear models, will be used to assess feasibility, baseline group differences, and the outcomes of the intervention.

Recruitment of participants began in Fall 2024. The completion of data collection is anticipated to be by Fall 2025.

The study results will give insight into the potential for an SMS text messaging–based CA to improve sleep in individuals who have survived BC and experience sleep disturbances.

ClinicalTrials.gov NCT06392789; https://clinicaltrials.gov/study/NCT06392789

DERR1-10.2196/62712

Figures